Les indicateurs médico-économiques et l’innovation en oncologie thoracique

2015, Developments in cancer treatments, market dynamics, patient access and value, Global Oncol Trend Rep 2015 Himmelstein, 2009, Medical bankruptcy in the United States, 2007 results of a national study, Am J Med, 122, 741, 10.1016/j.amjmed.2009.04.012 Luengo-Fernandez, 2013, Economic burden of cancer across the European Union: a population-based cost analysis, Lancet Oncol, 14, 1165, 10.1016/S1470-2045(13)70442-X Institut national du cancer. Les cancers en France en 2014-L’essentiel des faits et chiffres; 2015. CANMTS. CNAMTS. Dépenses de médicament de l’année 2014 et du premier semestre 2015; 2014. Chouaid, 2016, French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends, Target Oncol 2015, 11, 515, 10.1007/s11523-015-0411-8 Toumi, 2015, J Mark Access Health Policy, 18, A521 Ferner, 2010, NICE and new: appraising innovation, BMJ, 340, b5493, 10.1136/bmj.b5493 Aronson, 2012, Defining rewardable innovation in drug therapy, Nat Rev Drug Discov, 11, 253, 10.1038/nrd3715 Pietanza, 2016, Seeking New Approaches to Patients With Small Cell Lung Cancer, Am Soc Clin Oncol Educ Book, 35, e477, 10.14694/EDBK_158710 Hatz, 2014, Is individualized medicine more cost-effective? A systematic review, PharmacoEconomics, 32, 443, 10.1007/s40273-014-0143-0 Hillner, 2009, Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing, J Clin Oncol, 27, 2111, 10.1200/JCO.2008.21.0534 Collingridge, 2014, Affordable cancer care: pipedream or achievable reality?, Lancet Oncol, 15, 257, 10.1016/S1470-2045(14)70062-2 Chouaid, 2014, Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?, J Clin Oncol, 32, 3577, 10.1200/JCO.2014.56.2157 Cherny, 2015, A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS), Ann Oncol, 26, 1547, 10.1093/annonc/mdv249 Schnipper, 2015, American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options, J Clin Oncol, 33, 2563, 10.1200/JCO.2015.61.6706 Chouaïd, 2016, Disparités régionales et socio-économiques dans le cancer du poumon (étude TERRITOIRE), Rev Mal Respir, 33, A21, 10.1016/j.rmr.2015.10.047 Scherpereel, 2016, Accès aux médicaments de la « liste en sus » chez les patients atteints de cancer du poumon métastatique (étude TERRITOIRE), Rev Mal Respir, 33, A47, 10.1016/j.rmr.2015.10.677 Souquet, 2016, Délais d’accès à la chimiothérapie adjuvante après une chirurgie curative dans le cancer du poumon (étude TERRITOIRE), Rev Mal Respir, 33, A88, 10.1016/j.rmr.2015.10.112